The Filing Desk

Cue Biopharma

CUE · Nasdaq · Health Care · Financials, fiscal 2017 to 2025

CUE · Last close · November 19, 2026
$4.50
Value Cue Biopharma yourself

Cue Biopharma's revenue rose 195.8% to $28 million in fiscal 2025. Its operating margin was −96.7%, up from −446.9% a year earlier. Free cash flow was −$22 million. The diluted share count rose 68.2%.

Cue Biopharma, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 16, 2026 · 0001193125-26-108287 Updated
Revenue
$28M
195.8%
Operating margin
−96.7%
350.2 pts
Net income
−$27M
 
Free cash flow
−$22M
 
Return on equity
−121.1%
27.9 pts
Market cap
$48M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Cue Biopharma does

Cue Biopharma is a biotech company developing injectable drugs that aim to adjust specific parts of the immune system, called T cells, rather than boosting or suppressing it across the board. It is clinical-stage, which means it has no approved products and earns no revenue from selling medicines. Since July 2024 it has focused on autoimmune and inflammatory diseases, in which the immune system attacks the body's own tissue.

Its lead drug candidate, CUE-401, aims to restore immune balance by increasing regulatory T cells, the cells that keep the immune system in check. It has been tested only in animals so far, and Cue planned to file to start human trials in the second quarter of 2026. A second candidate, CUE-501, aims to direct existing T cells to destroy B cells that cause autoimmune disease; in April 2025 Cue licensed it to the drugmaker Boehringer Ingelheim. Its cancer candidates, CUE-101 and CUE-102, were licensed to ImmunoScape in November 2025. All of Cue's revenue so far has come from agreements with partners like these.

The company is based in Boston, Massachusetts, relies on outside firms to make its drugs and run its trials, and had 29 full-time employees at the end of 2025.

Its biggest risks, as it describes them

  • Its recurring losses raise substantial doubt about whether it can keep operating.
  • Its drug candidates may fail in testing or show side effects not seen in animal studies.
  • Relying on partners such as Boehringer Ingelheim, whose deals may not bring the benefits it expects and limit its own research.
  • Relying fully on outside firms to make its drug supplies, some from a single source, and to run its trials.
  • Competition from larger drugmakers working on treatments for the same diseases.
From Cue Biopharma's annual report on Form 10-K, filed March 16, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Cue Biopharma lost money in fiscal 2025: a net loss of $27 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments6476482227
Debt incl. finance leases084—0
Net debt (negative means net cash)−64−68−44—−27
Net debt to EBITDA—————
Debt to equity0.0x0.1x0.1x—0.0x
Interest coverage—−488.3x−521.5x−415.0x−265.5x
Current ratio5.3x6.7x3.0x1.8x2.7x
Quick ratio5.3x6.7x3.0x1.8x2.7x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Cue Biopharma's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $99,719 of Cue Biopharma shares on the open market, and 3 insiders sold $2.0 million.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Aug 13, 2026Shao-Lee LinChief Executive Officer, DirectorSold18,258$28.62$522,573Form 4
Aug 13, 2026Sumita RayChief Legal Compliance OfficerSold8,829$30.09$265,628Form 4
Aug 13, 2026Michael Vincent MeluzioVP, Prin. Accounting OfficerSold5,628$30.09$169,324Form 4
Aug 12, 2026Shao-Lee LinChief Executive Officer, DirectorSold40,000$27.10$1.1 millionForm 4
Dec 30, 2025Pasha SarrafDirectorBought323,857$0.31$99,719Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score4 of 8——
Rule of 40−386.9%−322.7%116.1%
Altman Z''−16.40−39.70−27.27
Accruals ratio−14.1%−9.3%−13.2%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassFailFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsPass——
Current ratio roseFailFailPass
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassPassPass
F-score4 of 8——
Companies that report no gross profit are scored on the other eight.

Compare

Put Cue Biopharma side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Cue BiopharmaFY25195.8%−96.7%−79.6%———
CelularityFY25−51.0%−230.9%————Compare
ScilexFY25−46.5%−1,143.7%12.2%——3Compare
Foghorn TherapeuticsFY2536.8%−279.5%−278.7%——2Compare
VerastemFY25209.1%−550.3%————Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

9 years of figures

Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue—1431516928
Revenue growth——202.7%−8.8%373.7%−91.7%341.0%69.2%195.8%
Gross profit—————————
Research and development192828344139413638
Operating income−23−39−37−45−44−53−52−42−27
Net income−23−39−37−45−44−53−51−41−27
Diluted EPS (US$)−2.16−1.94−1.66−1.56−1.41−1.49−1.11−0.72−0.28
Diluted shares (millions)112022293136465695
Cash flow
Cash from operations−12−26−31−32−39−42−40−36−22
Capital expenditure120110000
Free cash flow−13−28−31−33−40−42−40−36−22
Dividends paid000000000
Share buybacks000010000
Acquisitions000000000
Stock-based compensation376101210875
Balance sheet at fiscal year end
Cash and short-term investments643959856476482227
Debt incl. finance leases————084—0
Total assets6745721008391623242
Total liabilities51117211826241516
Shareholders' equity623455796666371826
Margins and ratios
Gross margin—————————
Operating margin—−3,386.7%−1,063.2%−1,428.0%−292.6%−4,275.1%−949.9%−446.9%−96.7%
Net margin—−3,411.5%−1,061.2%−1,419.8%−295.6%−4,257.8%−924.1%−438.0%−96.8%
Free cash flow margin—−2,473.8%−891.9%−1,049.0%−266.0%−3,371.7%−727.9%−391.9%−79.6%
Rule of 40 (growth + FCF margin)——−689.2%−1,057.8%107.6%−3,463.3%−386.9%−322.7%116.1%
Return on capital—————————
Return on equity—−81.6%−82.9%−67.1%−61.2%−80.8%−98.7%−149.0%−121.1%
Return on assets—−69.4%−62.8%−52.3%−48.3%−60.7%−66.4%−86.8%−71.5%
Net debt to EBITDA—————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Cue Biopharma's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Cue Biopharma.